Want to join the conversation?
$ENTA, specialized in creating small molecule drugs for viral infections and liver diseases, said the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for the use of VIEKIRAX EXVIERA without ribavirin in chronic hepatitis C virus infected genotype 1b patients with compensated cirrhosis.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.